Prostatac (PSA/IL-2/GM-CSF vaccine) / Theralink - LARVOL DELTA

Interim results of a phase Ia clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients (AACR 2018) - "...Prostate cancer may be an exception with the modest activity of sipuleucel-T...This study is a Phase 1a clinical trial of a PSA/IL-2/GM-CSF vaccine in 20 biochemically recurrent hormone-nave and hormone-independent prostate cancer patients...Interestingly, after vaccination 14 of 20 patients had an increase in the doubling time of their serum PSA, suggesting a slowing of the growth of the prostate cancer. Four of 20 patients have progressed (3 PSA progression and 1 radiological progression) at 31 weeks follow-up."

Clinical • P1 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

OncBioMune signs work order for phase 2 clinical trial of ProscaVax for early stage prostate cancer (GlobeNewswire) - P2, N=120; "OncBioMune Pharmaceuticals...today announces the signing of a work order with leading Contract Research Organization, Theradex Oncology...detailing the scope to be provided by Theradex for a clinical trial titled, 'A Phase 2, Randomized Study of ProscaVax, a PSA/IL-2/GM-CSF Vaccine, in Treatment-naïve Patients with Clinically Localized Prostate Cancer Versus and Active Surveillance Strategy.'  The trial, expected to enroll 120 patients..."

Enrollment status • Licensing / partnership • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

OncBioMune submits phase 2 protocol to Urology Centers of North Texas (GlobeNewswire) - "OncBioMune Pharmaceuticals, Inc....is pleased to inform shareholders that the Company on Tuesday, February 27, 2017 submitted the full protocol for the planned Phase 2 trial of ProscaVax for prostate cancer to Urology Centers of North Texas (UCNT) for review."

Clinical protocol • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

Prostatacancercentrum – navet i framtidens prostatacancersjukvård - En vision som är i linje med det nationella vårdprogrammets riktlinjer. (PubMed) - "Specialised prostate cancer units are increasingly common in Europe, but as yet there are no such units in Sweden. We believe that the creation of prostate cancer units in Sweden would be an essential step forward, towards an improved future care of men with prostate cancer."

Journal • Biosimilar • Genito-urinary Cancer • Oncology • Ophthalmology • Prostate Cancer • Solid Tumor • Urothelial Cancer

Site visit planned for december 19, 2018 to initiate phase 2 trial of ProscaVax for early-stage prostate cancer (GlobeNewswire) - "In the clinical trial, ProscaVax...is being evaluated for safety and efficacy in patients with low-risk localized prostate cancer compared to patients in 'Active Surveillance.'....OncBioMune has confirmed that a site visit is scheduled for December 19, 2018. This is the check-off meeting before beginning enrollment in the clinical trial, which is expected to transpire in the coming weeks."

Trial status • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

Phase 2 Trial of OncBioMune’s Immunotherapy Cancer Vaccine ProscaVax for Prostate Cancer Patients in Active Surveillance Now Open for Enrollment (GlobeNewswire, OncBioMune, L.L.C.) - "OncBioMune Pharmaceuticals...announces that the Phase 2, randomized study of ProscaVax in treatment-naïve patients with clinically localized prostate cancer vs active surveillance is now open for enrollment."

Clinical • Enrollment open

Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance (clinicaltrials.gov) - P2; N=120; Recruiting; Sponsor: OncBioMune Pharmaceuticals; Not yet recruiting ➔ Recruiting; Initiation date: Aug 2018 ➔ Feb 2019; Trial primary completion date: Aug 2020 ➔ Feb 2021

Clinical • Enrollment open • Trial initiation date • Trial primary completion date